Cequa carries a list price of roughly $600 to $700 for a monthly supply, making it one of the pricier prescription eye drops on the market. Several factors drive that cost: a patented delivery technology with no generic equivalent, a supply chain where middlemen inflate list prices, and limited competition in its specific drug class.
What Makes Cequa Different From Older Options
Cequa’s active ingredient, cyclosporine, isn’t new. It’s the same immune-modulating compound found in Restasis, which has been treating dry eye disease for over two decades. What separates Cequa is how that ingredient gets into your eye. Cyclosporine is extremely water-resistant, so older formulations relied on oily emulsions to deliver it. These oil-based drops can blur vision temporarily and cause stinging or discomfort.
Cequa uses a proprietary system called NCELL, which wraps cyclosporine molecules inside tiny structures called nanomicelles. The result is a clear, water-based, preservative-free solution that can deliver a higher concentration of cyclosporine (0.09%, compared to Restasis’s 0.05%) with less irritation. Developing that technology required years of research and clinical trials, and the manufacturer, Sun Pharmaceutical Industries, holds patents on the formulation. Those patents block competitors from making a copy, and no generic version of Cequa has been approved by the FDA.
How Clinical Trial Results Factor In
To win FDA approval, Cequa had to prove it meaningfully increased tear production. In the pivotal clinical trial, researchers measured how many patients saw a significant jump in tear output after 84 days. About 16.6% of eyes treated with Cequa hit that benchmark, compared to 9.2% on placebo drops. A second study showed similar numbers: 16.8% versus 8.6%.
Those differences were statistically significant, but the absolute numbers highlight something important about dry eye treatment in general. No single drop works dramatically for every patient. Manufacturers price these drugs partly to recoup development costs across a patient population where the response rate is modest. When only a fraction of patients see large improvements, the per-patient cost of bringing the drug to market goes up.
The Role of Middlemen in Drug Pricing
A big chunk of Cequa’s sticker price never reaches the manufacturer. Pharmacy benefit managers, the companies that negotiate drug prices on behalf of insurance plans, play a major role in inflating list prices across the pharmaceutical industry. Here’s how it works: PBMs control which drugs land on an insurance plan’s preferred list. To earn that favorable placement, manufacturers pay rebates back to PBMs. In 2022, rebates and related price concessions across all brand-name drugs totaled an estimated $223 billion.
The catch is that manufacturers often raise their list price to absorb these rebate payments while maintaining their revenue. So the price you see at the pharmacy counter is artificially high. If you have insurance, your PBM may have negotiated a lower net price, but your copay is typically calculated from the inflated list price. If you’re uninsured or your plan doesn’t cover Cequa, you’re facing the full amount. This system particularly punishes specialty drugs like Cequa that sit in a small therapeutic category with few direct competitors vying for formulary space.
Limited Competition Keeps Prices High
The prescription dry eye market has relatively few players. For cyclosporine-based drops specifically, your main options are Restasis (now available as a generic in its 0.05% emulsion form), Cequa, and a handful of newer entries like Vevye. Restasis generics have brought some price relief to that corner of the market, but they use the older oil-based formulation at a lower concentration. They aren’t direct substitutes for Cequa’s nanomicellar technology.
Without a generic equivalent or a bioequivalent competitor, Sun Pharma faces little pressure to lower Cequa’s price. Patent protection on the NCELL delivery system is the primary barrier. Until those patents expire and generic manufacturers can replicate the formulation, pricing power stays with the original maker.
Ways to Reduce Your Out-of-Pocket Cost
If your doctor has prescribed Cequa and the price is a barrier, a few options exist. Sun Pharma offers a copay assistance program for patients with commercial insurance that can reduce what you pay at the pharmacy. The company also partners with PhilRx, a third-party pharmacy service, to offer additional savings for eligible patients. You can reach both programs by calling 855-268-1426 or visiting the manufacturer’s website.
If you don’t qualify for those programs, it’s worth asking your ophthalmologist whether a generic cyclosporine 0.05% drop or a different class of dry eye medication could work for your situation. The higher concentration and improved delivery in Cequa matters most for patients who haven’t responded well to older formulations. For others, a less expensive alternative may provide adequate relief.